Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras

Experimental Cell Research

Volumn 273, Issue 2, 2002, Pages 138-146

  Brassard, Diana L ^a   English, Jessie M ^a   Malkowski, Michael ^a   Kirschmeier, Paul ^a   Nagabhushan, T L ^a   Bishop, W Robert ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE 1;

APOPTOSIS; ARTICLE; BIOTRANSFORMATION; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR REGRESSION;

MUS MUSCULUS;

EID: 0036061374     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2001.5440     Document Type: Article

References (38)

1. Increasing complexity of Ras signaling
2. Novel tricyclic inhibitors of farnesyl protein transferase: Biochemical characterization and inhibition of Ras modification in transfected Cos cells
3. Resistance of K-RasB-V12 proteins to farnesylation inhibitors in Rat1 cells
4. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
5. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
6. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
7. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
8. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
9. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase inhibitor, in human tumor xenograft models and WAP-Ras transgenic mice
10. A farnesyl transferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
11. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
12. Signal transduction through MAP kinase cascades
13. A synthetic inhibitor of the mitogen-activated protein kinase cascade
14. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
15. Evidence of cell-specific differences in transformation by N-, H-, and K-ras
16. Harvey Ras results in a higher frequency of mammary carcinomas than Kirsten Ras after direct retroviral transfer into rat mammary gland
17. The C-terminal polysine region and methylation of K-ras are critical for the interaction between K-ras and microtubules
18. A genome-wide survey of Ras transformation targets
19. Ras pathway specificity is determined by the integration of multiple signal-activated and tissue-restricted transcription factors
20. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase
21. Four human Ras homologues differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility
22. Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo
23. (+)-4-[2-[4-(8-Chloro-3, 10-dibromo-6, 11-dihydro-5H-benzo[5, 6]cyclohepta[1, 2-b]-pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent
24. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells
25. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein
26. Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences
27. 3 mediated activation of apoptosis
28. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays
29. Farnesyltransferase inhibitors induce cytochrome c release and caspase-3 activation preferentially in transformed cells
30. New insights into the control of MAP kinase pathways
31. Constitutive activation of the 41/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
32. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
33. Cdk inhibitors, roscovitine, and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines
34. The search for physiological substrates of MAPK and SAPK kinases in mammalian cells
35. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment
36. Activation of the PI3K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors
37. Prenylation of target GTPases contributes to signaling specificity of ras-guanine nucleotide exchange factors
38. Differential activation of the Rac pathway by Ha-Ras and K-Ras